An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated with Opioids Chronically

04/03/2016
02/07/2024
EU PAS number:
EUPAS12669
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

D3820R00009 CSP - PRAC 07312015 final

English (418.76 KB - PDF) View document
Updated protocol

m1-8-2 D3820R00009 PASS CSP_v6.1_29Mar2021

First published: 22/02/2024
English (1.25 MB - PDF) View document
Study results
Study results

Naloxegol_SES_final report_2022_V1.0_Abstract

English (595.05 KB - PDF) View document
Study report
Other information